RVMD 10-Q filed 2026-11-04 | Key takeaways
RVMD filed its 10-Q; the most relevant disclosure change is added Product revenue recognition: Company began recognizing net product revenue from RASONQUE in Q3 2026 following FDA approval in August 2026, recording $197.6 million in product revenue, net for the three and nine months ended September 30, 2026. Revenue is recognized at the transaction pric. Customer concentration: Customer A represented 71% of net_sales; Customer B represented 28% of net_sales.
Key takeaways
Customer concentration: Two customers accounted for 71% and 28% of total net product revenue for Q3 and nine months ended September 30, 2026; same customers represented 72% and 28% of accounts receivable balance.
Net loss: Q3 2026 net loss of $407.5 million ($1.90 per share) compared to $305.2 million ($1.61 per share) in Q3 2025; nine-month net loss was $1.505 billion versus $766.4 million year-over-year.
R&D expenses: Increased 59% year-over-year to $417.1 million in Q3 2026, driven by higher clinical trial and manufacturing costs including pre-launch inventory expenses, with zoldonrasib expenses up $47.2 million and RASONQUE expenses up $29.8 million.
SG&A expenses: Increased 191% year-over-year to $153.3 million in Q3 2026, reflecting $41.7 million increase in commercial expenses and $36.1 million increase in employee-related costs to support RASONQUE commercialization.
Capital raises: April 2026 follow-on offering raised $1.65 billion net and 0.50% convertible senior notes due 2033 raised $487.1 million net; cash position increased to $3.7 billion from $2.0 billion at year-end 2025.
Subsequent events: In October 2026, company drew first $250 million tranche of term loan facility following FDA approval and entered BMS collaboration for pumitamig (BNT327) in four study cohorts across PDAC, NSCLC, and CRC.
Intangible assets: Acquired RAS programs IPR&D of $55.8 million reclassified to finite-lived intangible assets following FDA approval of RASONQUE, with amortization beginning prospectively over 17-year useful life.
Key metrics
Customer concentration
Disclosure changes
- Product revenue recognition
Company began recognizing net product revenue from RASONQUE in Q3 2026 following FDA approval in August 2026, recording $197.6 million in product revenue, net for the three and nine months ended September 30, 2026. Revenue is recognized at the transaction price when the customer obtains control of the product, generally upon delivery, and includes adjustments for variable consideration such as government rebates, chargebacks, cash discounts, product returns and other deductions.
First revenue from commercial product launch provides visibility into RASONQUE commercial trajectory and establishes a revenue base for the company. - Customer concentration
Two individual customers accounted for 71% and 28% of total net product revenue for each of the three and nine months ended September 30, 2026. As of September 30, 2026, two customers accounted for 72% and 28% of the accounts receivable balance of $230.7 million.
High customer concentration creates revenue and credit risk exposure to a limited number of specialty pharmacy customers. - Accounts receivable and inventory
Company reported accounts receivable, net of $230.7 million and inventory of $11.0 million as of September 30, 2026, both of which were zero at December 31, 2025, reflecting the commencement of RASONQUE commercial sales.
First balance sheet receivables and inventory from product sales provide insight into commercial launch progress and working capital needs. - Accrued rebates
Company reported accrued rebates of $44.7 million as of September 30, 2026, included within accrued expenses and other current liabilities of $365.6 million, reflecting variable consideration estimates for government rebate obligations under ASC 606.
Accrued rebates represent gross-to-net adjustments under revenue recognition accounting and affect net product revenue quality. - Convertible senior notes
In April 2026, company issued $500 million aggregate principal of 0.50% convertible senior notes due 2033, with net proceeds of $487.1 million. Notes bear interest at 0.50% per year payable semi-annually, with initial conversion rate of 5.0302 shares per $1,000 principal (conversion price ~$198.80). Carrying value as of September 30, 2026 was $487.9 million.
New debt financing of $500 million adds to company's capital structure and introduces interest expense and potential dilution from conversion. - Term loan facility
First tranche of $250 million term loan drawn in October 2026 following FDA approval of RASONQUE, with 2.0% upfront fee of $5.0 million paid. Loan bears interest at three-month SOFR (floor 3.5%) plus 5.75%, interest-only with principal due October 8, 2032. Second and third tranches of $250 million each remain optional and may be drawn upon achievement of specified commercial milestones prior to January 1, 2028.
Term loan draws increase cash position but add debt obligations with specific milestone triggers for remaining tranches.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow RVMD in real time
Get material earnings, filing, IR, and earnings-call alerts by email.